Sat, Jul 12, 2014, 6:31 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Apricus Biosciences, Inc. Message Board

canstic1 229 posts  |  Last Activity: 19 hours ago Member since: Jul 13, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • canstic1 canstic1 19 hours ago Flag

    BSDM CEO said Terumo has penetrated only about 50 of the 100 countries of area they cover. There is still a lot more to go. Terumo is investing a lot of money to demonstrate and teach the IR community about MWA and MicroThermX. Terumo is a 5 billion dollar company with 8 billion dollars in sales. They don't sell just a "few" of anything. They sell in the millions or they don't sell at all. Remember that.

    Distribution deal can happen any day now for ASIA.

    That was made clear on the conference call.

    Some phrases he used about a deal with one of the three multi-billion dollar companies they are currently in talks with (and Butch Wolcott is ultra-conservative) were the following:

    "overnight game changer"

    would "change the face of the company"

    "companies are pursuing BSDM"

    He used very powerful words and statements. Still waiting for transcript to be released.

    The Terumo deal took one year of negotiations before it was signed. This new deal is in talks for some time already, with 3 companies. I think the insider stock buys made in early May were made because of how close they are to this new deal. Just an observation and my opinion. Keep in mind it was the first time in 5 years that any insiders bought open market stock. Makes you wonder why then?.......

  • canstic1 canstic1 19 hours ago Flag

    “Our healthy growth in revenues for the first nine months of this year has been driven by the strategic roll-out of our microwave ablation MicroThermX® system by Terumo and increasing sales of our SynchroWave disposable antennas. Revenues were slightly lower in the third quarter due to the large number of MTX systems shipped in the same quarter last year following the signing of our distribution agreement with Terumo; however, we continue to see robust interest and adoption from our partnership, as evidenced by the 50% growth in total antennae sales through the first nine months of the year,” said Harold Wolcott, President of BSD Medical. “In addition, year-to-date we’ve sold a total of six hyperthermia systems, including three to our distributor in Taiwan with the anticipated sale of a fourth system to that distributor in the current quarter.

    “While growing revenues we have kept tight control over operating expenses and reduced our year-to-date net loss by more than $1 million. With our costs in check and recently strengthened cash position, we are well positioned for continued growth,” added Mr. Wolcott. “Terumo is an excellent distribution partner for the MTX product line, with exclusive license to sell in more than 100 countries in the greater Europe area, and we are seeing growing interest in that part of the world. There is an emerging body of evidence and acceptance of the use of microwave ablation technology in the treatment of cancer, both domestically and abroad, which bodes well for BSD’s future.”

  • canstic1 canstic1 21 hours ago Flag

    Just said that there are three (3) multi billion dollar distributors that are pursuing the rights to market MicroThermX (in Asia?)...important to note is that BSDM is being PURSUED by these companies, they came to BSDM...

    CEO called this a game changing event that could happen overnight and would change the face of the company. They have been in negotiations for some time now and said these talks are going well.

    Terumo deal took some time also. It will come. It will be huge for BSDM. Sales are developing. It is happening

  • canstic1 canstic1 Jul 10, 2014 2:50 PM Flag

    goingeasy, there have delays, not "lies" as you put it. That is normal business delays. I can accept that. You should either accept it and look at this as a great opportunity, or consider them "lies" and sell your stock take the tax loss and move on. It's really that simple.

  • canstic1 canstic1 Jul 10, 2014 2:49 PM Flag

    I understood it to mean distribution deals for MicroThermX in Asia. I will have to listen to the replay later to clarify it. Either way, it bodes well for BSDM that major companies are coming to them. CEO made a point of stressing that fact. They came to BSDM, not the other way around.

    On a side note, slow as this horse has been to get in the race, I still like the prospectsgoing forward. I liked it at $1.35, so I must love it at 0.88$

    I am adding to my position today.

    I noticed someone sold a block of 100,000 shares at 0.8724 before noon today. That may weigh on the price a bit as the MM who took it in churns it back out. Looks like someone decided to get out before the conference call. Good for them. No one should own this stock if they do not believe what they heard in the CC today. I believe. I am buying.

  • Just said that there are three (3) multi billion dollar distributors that are pursuing the rights to market MicroThermX (in Asia?)...important to note is that BSDM is being PURSUED by these companies, they came to BSDM...

    CEO called this a game changing event that could happen overnight and would change the face of the company. They have been in negotiations for some time now and said these talks are going well.

    Terumo deal took some time also. It will come. It will be huge for BSDM. Sales are developing. It is happening.

  • Comed Medical Specialties is the number one specialty medical distributor in the Western United States. Comed has a thirty-year history of selling innovative medical devices to the interventional radiology market. Comed has well-established, key relationships with department heads at interventional radiology institutions throughout the West. Comed has 10 sales personnel specializing in selling innovative surgical and interventional radiology products.

    Based in Salt Lake City, Utah, Comed has the rights to market the MicroThermXline of products in Arizona, California, Colorado, El Paso, Texas, Nevada, New Mexico, and Utah. Comed’s sales team will work hand-in-hand with BSD sales management and BSD’s direct sales representatives and clinical specialist in the West to penetrate one of the largest target markets for MicroThermX products in the United States.

    “We are pleased to partner with a distributor of Comed’s caliber in interventional radiology products, as this is another essential step in presenting the advantages of the MicroThermX to opinion leaders throughout the West,” said Brian Ferrand, BSD Vice President of Domestic Sales. “Comed has long-established relationships with key interventional radiologists and capital equipment purchasers, which will increase sales of our products in the Western United States.”

    “The chance to distribute BSD’s MicrothermX product line is exceptionally attractive to Comed,” said Mike Mahoney, Principal with Comed. “Microwave ablation technology is in a rapidly growing market sector for treating cancer and Comed sees a tremendous opportunity to offer MicroThermX to its extensive base of established customers.”

  • “Our healthy growth in revenues for the first nine months of this year has been driven by the strategic roll-out of our microwave ablation MicroThermX® system by Terumo and increasing sales of our SynchroWave disposable antennas. Revenues were slightly lower in the third quarter due to the large number of MTX systems shipped in the same quarter last year following the signing of our distribution agreement with Terumo; however, we continue to see robust interest and adoption from our partnership, as evidenced by the 50% growth in total antennae sales through the first nine months of the year,” said Harold Wolcott, President of BSD Medical. “In addition, year-to-date we’ve sold a total of six hyperthermia systems, including three to our distributor in Taiwan with the anticipated sale of a fourth system to that distributor in the current quarter.

    “While growing revenues we have kept tight control over operating expenses and reduced our year-to-date net loss by more than $1 million. With our costs in check and recently strengthened cash position, we are well positioned for continued growth,” added Mr. Wolcott. “Terumo is an excellent distribution partner for the MTX product line, with exclusive license to sell in more than 100 countries in the greater Europe area, and we are seeing growing interest in that part of the world. There is an emerging body of evidence and acceptance of the use of microwave ablation technology in the treatment of cancer, both domestically and abroad, which bodes well for BSD’s future.”

  • canstic1 canstic1 Jul 9, 2014 8:36 AM Flag

    " Good growth does not look for a new CEO. "

    He is 72+ years old and his contract ran out. He always said he would retire at that point. And he is. Performance has nothing to do with his leaving the company. Besides, the company needs someone younger up to the travel challenge. He is on the road 50% of the year. It's a Global business, a multi-billion dollar global business. Don't forget that. I am looking forward to hearing about a distribution agreement in Asia (highest rates of HCC occur there) at tomorrows Conference call.

  • canstic1 canstic1 Jul 9, 2014 8:31 AM Flag

    See the BSD website for information about listening and asking questions.

    Lots of lies on this board posted by need ID's this past week. The company will show good growth in sales. It will mark the third consecutive quarter of solid growth. The company is solid with 11+ million dollars in the bank which is 2+ years of operating capital. NO DEBT. Growing sales. These are facts

  • Reply to

    DO THE MATH. BSDM has nowhere to go but UP.

    by canstic1 Mar 31, 2014 9:38 AM
    canstic1 canstic1 Jul 9, 2014 8:24 AM Flag

    CEO stated very clearly that one interventional oncologist in a big cancer facility could easily do FIVE PROCEDURES IN ONE WEEK. That would be 260 procedures in 1 year. He also stated on another question that right now 1.5 antennas is the average usage rate. 1.5 times 260 equals 390 antennas used in one year.

    I was told by someone who uses antennas that they cost $2,750. BUT, lets be conservative and go with a number given to me by BSDM some time ago, $2,000 per antenna.

    390 antennas at $2,000 each equals $780,000 is sales revenues generated from just ONE HOSPITAL. (actually I think he said ONE RADIOLOGIST in a large hospital, so it could be much more, yes?)

    Imagine at some point 100 hospitals, large cancer facilities using the BSDM MicroThermX. Sales would be 100 times $780,000 which equals 78 million dollars in revenues in 1 year. Remember it's a GLOBAL business.

    I expect at some point in the future that there will be several hundred MicroThermx is use around the world. That is a very easy number to imagine. Look into the number of RFA ablation systems in use around the world. It's in the thousands, maybe tens of thousands.

    Microwave is becoming standard of care because it's BETTER than RFA. But it takes time. BSDM will get there. If you cannot see a future with sales in excess of 100 million dollars, then I think you should sell your stock. Everyone. Sell it.

    I see 100, 200, 300 million is sales down the road. And we have not even touched on the other BSDM product lines. It will happen. I am comfortably long. The downside in my opinion is very very limited. About 45 million shares outstanding, under 50 million dollar market cap, with hundreds of millions in sales on the way. Nowhere to go but UP, in my opinion.

  • canstic1 canstic1 Jul 9, 2014 8:19 AM Flag

    BSD’s exclusive, multi-million dollar agreement with Terumo covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa, with a market potential that exceeds $1 billion.

    “Terumo is implementing a well-planned marketing strategy for the MicroThermX aimed at geographic expansion,” said Sam Maravich, Vice President of International Sales and Marketing of BSD Medical. “We are gaining sales traction in the Western European countries. Terumo is an exceptional partner for BSD, making substantial investments in sales and marketing of the MicroThermX.”

    About Terumo Corporation

    A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

    Nothing to do but wait to see the numbers and the growth next week. Sales growing every Q now, no reason for them to slow down

  • Reply to

    INSIDER BUYING AT BSDM

    by canstic1 Jun 11, 2014 10:06 PM
    canstic1 canstic1 Jul 9, 2014 8:18 AM Flag

    Do you really think insiders bought right before announcing a bad quarter? Or do you think they bought before announcing a GOOD quarter? Use you heads....

    William S. Barth CFO BSD Medical, purchased 18,500 shares on the open market May 13, 2014

    Timothy McQuay, director bought 2,500 shares of BSDM May 14, 2014

    Butch Wolcott, CEO bought 7,500 shares BSDM, May 14, 2014

    That makes 3 company insiders buying stock in the last 2 weeks. This is very telling, in my opinion.

    There has been no insider buying in 5 years.

    AND, the departing CEO is NOT selling. He is buying more.

    Insiders BUY for only one reason. They think (know) the stock is headed higher.

    Check Edgar or Insider Cow to see the filings.

    These are indeed OPEN MARKET PURCHASES. They are the first ones in years.

    Insider buying, new financing plan, 11+ million cash (they burn only 500,000 a month), no debt, Terumo distributorship with growing sales, approval for BSD-2000 in Taiwan, and much more good news has created an atmosphere where insiders will finally make open market buys. No doubt we will see more filings in the coming day

  • Reply to

    INSIDER BUYING AT BSDM

    by canstic1 Jun 11, 2014 10:06 PM
    canstic1 canstic1 Jul 7, 2014 7:59 PM Flag

    Do you really think insiders bought right before announcing a bad quarter? Or do you think they bought before announcing a GOOD quarter? Use you heads....

    William S. Barth CFO BSD Medical, purchased 18,500 shares on the open market May 13, 2014

    Timothy McQuay, director bought 2,500 shares of BSDM May 14, 2014

    Butch Wolcott, CEO bought 7,500 shares BSDM, May 14, 2014

    That makes 3 company insiders buying stock in the last 2 months. This is very telling, in my opinion.

    There has been no insider buying in 5 years.

    AND, the departing CEO is NOT selling. He is buying more.

    Insiders BUY for only one reason. They think (know) the stock is headed higher.

    Check Edgar or Insider Cow to see the filings.

    These are indeed OPEN MARKET PURCHASES. They are the first ones in years.

    Insider buying, new financing plan, 11+ million cash (they burn only 500,000 a month), no debt, Terumo distributorship with growing sales, approval for BSD-2000 in Taiwan, and much more good news has created an atmosphere where insiders will finally make open market buys. No doubt we will see more filings in the coming days

  • canstic1 canstic1 Jul 7, 2014 6:33 PM Flag

    "We are excited to have this prestigious cancer center agree to serve as a teaching center and a Center of Excellence for the MicroThermX," said Harold Wolcott, President of BSD Medical. "Setting up teaching centers throughout the U.S. is part of BSD's comprehensive marketing strategy to build the network of physicians using the MicroThermX and thus increase BSD's market share. HCI will serve as a comprehensive resource and training center for academic and clinical training on microwave ablation treatments using the MicroThermX for both current and future physicians and researchers."

    About Huntsman Cancer Institute

    Huntsman Cancer Institute (HCI) is part of the University of Utah Health Care system. HCI is a National Cancer Institute (NCI)-Designated Cancer Center, which means it meets the highest standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer. HCI serves thousands of cancer patients throughout the Intermountain West every year and provides academic and clinical training for future physicians and researchers. Patients are referred to HCI from a broad, multistate region. HCI ensures that every person receives excellent cancer care and is able to benefit from the latest advances in cancer diagnosis, treatment, and prevention strategies through participation in clinical trials.

  • canstic1 canstic1 Jul 7, 2014 6:27 PM Flag

    See the BSD website for information about listening and asking questions.

    Lots of lies on this board posted by need ID's this past week. The company will show good growth in sales. It will mark the third consecutive quarter of solid growth. The company is solid with 11+ million dollars in the bank which is 2+ years of operating capital. NO DEBT. Growing sales. These are facts.

  • canstic1 canstic1 Jul 7, 2014 9:57 AM Flag

    “We are gaining sales traction in the Western European countries. Terumo is an exceptional partner for BSD, making substantial investments in sales and marketing of the MicroThermX.”

  • Reply to

    INSIDER BUYING AT BSDM

    by canstic1 Jun 11, 2014 10:06 PM
    canstic1 canstic1 Jul 7, 2014 9:55 AM Flag

    Do you really think insiders bought right before announcing a bad quarter? Or do you think they bought before announcing a GOOD quarter? Use you heads....

    William S. Barth CFO BSD Medical, purchased 18,500 shares on the open market May 13, 2014

    Timothy McQuay, director bought 2,500 shares of BSDM May 14, 2014

    Butch Wolcott, CEO bought 7,500 shares BSDM, May 14, 2014

    That makes 3 company insiders buying stock in the last 2 weeks. This is very telling, in my opinion.

    There has been no insider buying in 5 years.

    AND, the departing CEO is NOT selling. He is buying more.

    Insiders BUY for only one reason. They think (know) the stock is headed higher.

    Check Edgar or Insider Cow to see the filings.

    These are indeed OPEN MARKET PURCHASES. They are the first ones in years.

    Insider buying, new financing plan, 11+ million cash (they burn only 500,000 a month), no debt, Terumo distributorship with growing sales, approval for BSD-2000 in Taiwan, and much more good news has created an atmosphere where insiders will finally make open market buys. No doubt we will see more filings in the coming days

  • See the BSD website for information about listening and asking questions.

    Lots of lies on this board posted by need ID's this past week. The company will show good growth in sales. It will mark the third consecutive quarter of solid growth. The company is solid with 11+ million dollars in the bank which is 2+ years of operating capital. NO DEBT. Growing sales. These are facts.

  • "We are excited to have this prestigious cancer center agree to serve as a teaching center and a Center of Excellence for the MicroThermX," said Harold Wolcott, President of BSD Medical. "Setting up teaching centers throughout the U.S. is part of BSD's comprehensive marketing strategy to build the network of physicians using the MicroThermX and thus increase BSD's market share. HCI will serve as a comprehensive resource and training center for academic and clinical training on microwave ablation treatments using the MicroThermX for both current and future physicians and researchers."

    About Huntsman Cancer Institute

    Huntsman Cancer Institute (HCI) is part of the University of Utah Health Care system. HCI is a National Cancer Institute (NCI)-Designated Cancer Center, which means it meets the highest standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer. HCI serves thousands of cancer patients throughout the Intermountain West every year and provides academic and clinical training for future physicians and researchers. Patients are referred to HCI from a broad, multistate region. HCI ensures that every person receives excellent cancer care and is able to benefit from the latest advances in cancer diagnosis, treatment, and prevention strategies through participation in clinical trials.

APRI
2.09+0.01(+0.48%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.